MedTrace Logo

Regorafenib Phase I Study in Mainland Chinese Patients

NCT02398513 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-08-01

No results posted yet for this study

Summary

The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors.

The second objective include the evaluation of safety, tolerability, and efficacy of Chinese patents treated with Regorafenib

Conditions

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Regorafenib 160 mg per oral

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-11-30
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02398513 on ClinicalTrials.gov